Leveraging advancements in spatially resolved single-cell profiling, our study enhances understanding of glioma evolution and the complex tumor microenvironment. Through spatially resolved multi-omic analysis of glioma samples from different treatments and stages, we've mapped glioblastoma's architectural changes over time, highlighting mechanisms behind therapy resistance. Our use of array-based and in-situ transcriptomics across treatment types revealed key transcriptional programs related to resistance, showing significant inter-patient heterogeneity and unique resistance pathways in recurrent tumors. We identified  adaptations in the neural and immune microenvironment shifts post-immunotherapy, indicating mechanisms of resistance development. By integrating spatial transcriptomics and clinical data into graph-neural networks, we've created models predicting treatment responses, offering new insights for precision oncology.

Genome editing as a tool to generate different combinations of mutations across clones, modeling cancer, has been widely adopted by researchers who are looking to recapitulate disease in a humanized model. However, CRISPR-induced gene editing can result in heterogeneous editing outcomes such as variations in zygosity, off-target effects, and co-occurring multiplex edits. In particular, measurement of multiplex gene editing has posed a challenge. Measuring these outcomes accurately cannot be done by traditional sequencing without lengthy clonal outgrowth steps and hours of computational work. 

Sepakers topics:

• Discuss how single-cell DNA sequencing provided insights into the mutant-specific alterations involved in leukemic transformation from premalignant clonal hematopoiesis to AML
• Share how they generated an integrated multi-recombinase (Cre, Flp, and Dre) tool (genetically engineered mouse models) for modeling reversible, sequential mutagenesis from premalignant clonal hematopoiesis to acute myeloid leukemia. 
• Used single-cell DNA sequencing to model sequential mutagenesis and deterministically investigate mechanisms of transformation and oncogenic dependency in the context of clonal evolution.
• Share thoughts/perspective on the importance of building disease models that can recapitulate human disease and how single-cell DNA sequencing can be a useful confirmation tool.
• The utility of single-cell DNA sequencing for mutation characterization and DNA aberrations
• How top academic and pharma institutions are leveraging single-cell DNA multi-omics to validate disease models

Speakers:
Robert Bowman, PhD
Assistant Professor of Cancer Biology
University of Pennsylvania Perelman School of Medicine

Matthew Cato
Vice President, Business Development @ Mission Bio

It is our pleasure to welcome you to the Swiss Physiology Meeting 2024!

Inspiring the Future of Chemistry and Life Sciences.

Stop by at our booth B153!

Ilmac has its origins in the Swiss trade fair for international laboratory, measurement and automation technology in chemistry, which has been held since 1959. Today, the chemistry and life science brand networks the industry both physically and digitally.

With its value proposition “Inspiring the Future of Chemistry and Life Sciences”, it encourages the development of new ideas and solutions and presents trends and innovations from research and industry at significant locations such as Basel and Lausanne.